Discovers and clinically develops novel therapeutic solutions leveraging cannabinoids. Focuses on enhancing patients' quality of life through innovative drug development. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
Executives buying with their own money is usually read as confidence in the company’s future.
The stock trades 44% below its peak. The market has trimmed its expectations for the company.
Over the last 12 months, company executives reported 12 buys and 1 sell. Management buying with its own money is usually read as a good sign.
A loss of $1.3M against $0 in annual sales.
At the current pace of spending, the cash lasts less than a year. After that, the company needs to find new money.
No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: earnings execution, the revenue breakdown.